Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guoling Yang

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Pathogens (Basel, Switzerland)|December 31, 2025
Association of Antimicrobial Susceptibility with Treatment Response in <i>Mycobacterium avium complex</i> Pulmonary DiseaseXuejiao Luo, Yuhang Chen, Lina Davies Forsman, et al.
Vaccine|July 17, 2024
Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059]Fei Jin, Lei Zhu, Yunpeng Wang, et al.
Vaccine|June 27, 2024
Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographicFei Jin, Lei Zhu, Yunpeng Wang, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Pathogens (Basel, Switzerland)|December 31, 2025
Association of Antimicrobial Susceptibility with Treatment Response in <i>Mycobacterium avium complex</i> Pulmonary DiseaseXuejiao Luo, Yuhang Chen, Lina Davies Forsman, et al.
Vaccine|July 17, 2024
Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059]Fei Jin, Lei Zhu, Yunpeng Wang, et al.
Vaccine|June 27, 2024
Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographicFei Jin, Lei Zhu, Yunpeng Wang, et al.
Pageof 3